natgillin/translations-raw huggingface dataset:
The container according to claim 2, wherein the outlet opening is located between prongs of the Y-shaped structure defined by the first branch, the first branch surrounding the outlet opening. 
Spremnik prema zahtjevu 3, naznačen time da je izlazni otvor (5) smješten između krakova strukture Y oblika definirane pomoću prvog ogranka (22), prvi ogranak (22) okružuje izlazni otvor (5).
The use of item 43, wherein the cancer is selected from the group consisting of colorectal cancer, non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer and breast cancer. The invention as described hereinabove. 
Protutijelo ili pripravak za uporabu prema zahtjevu 18, naznačen/o time, da je rak odabran iz skupine koja se sastoji od raka debelog crijeva, raka ne-malih stanica pluća (NSCLC), raka želuca, raka gušterače i raka dojke.
The method of claim 2, wherein the at least one pro-inflammatory cytokine comprises an IL-17 cytokine selected from the group consisting of: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. The method of claim 2, wherein the at least one pro-inflammatory cytokine comprises a cytokine selected from the group consisting of: IFN-Y, IL-113, RANTES, MIP-1a, IL-8, and IL-6. The method of claim 1, wherein the disorder mediated by the Th17 pathway is selected from the group consisting of: uveitis, multiple sclerosis, arthritis, neuromyelitis optica, psoriasis, systemic lupus erythematosus, an inflammatory bowel disease, celiac disease, asthma, chronic obstructive pulmonary disease (COPD), scleritis, vasculitis, Behcet's disease, atherosclerosis, atopic dermatitis, emphysema, periodontitis, allergic rhinitis, and allograft rejection. 
Sastav za upotrebu prema zahtjevu 1, gdje je sastav za upotrebu u postupku liječenja ili sprječavanja bolesti ili stanja izabranog iz grupe koju čine astma, kao što je alergijska astma ili neutrofilna astma; artritis, kao što je reumatoidni artritis, osteoartritis, psorijatični artritis, ili dječji idiopatski artritis; multipla skleroza; optički neuromijelitis (Devicova bolest); ankilozantni spondilitis; spondiloartritis; psorijaza; sistemski eritemski lupus; upalna bolest crijeva, kao što je Crohnova bolest ili ulcerozni kolitis; celijakija; kronična opstruktivna plućna bolest (COPD); uveitis; skleritis; vaskulitis; Behcetova bolest; ateroskleroza; atopijski dermatitis; emfizem; periodontitis; alergijski rinitis; i odbacivanje alografta.
The particulate recycled cathode material according to any one of claims 9 to 11, which contains less than 1 percent by weight of water based on the total weight of the recycled cathode material. 
Upotreba usitnjenih čestica recikliranog katodnog materijala u skladu s bilo kojim od patentnih zahtjeva 7 1li 8, naznačena time, da sadržava manje od 1 težinskog postotka vode na temelju ukupne težine materijala reciklirane katode.
a filler in an amount of about 86.5% to about 99.8%, by weight as a percentage of total weight; and/or 
gdje je lubrikant, kada je prisutan, prisutan u količini do oko 1.5%, prema težini kao postotak ukupne težine, na primjer u količini od oko 1%, prema težini kao postotak ukupne težine; i/ili
The resulting effect in the mesolimbic tract reduces hallucinations and delusions. 
Rezultirajući učinak u mezolimbičnom traktu smanjuje halucinacije i iluzije.
An oral formulation for use according to claims 1-3 for administering in conjunction with one or more additional therapeutic agents for the treatment of neovascular disorders. 
Upotreba u skladu s patentnim zahtjevima 15-18, naznačena time što medikament se primijenjuje uz jedno ili više dodatnih terapijskih sredstava za liječenje neovaskularnih poremećaja.
converting the vinylaniline compound to a methyl, t-butyl carbamate derivative; 
pretvorbu vinilanilinskog spoja u metil-t-butil-karbamatni derivat;
comprises a heavy chain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:88; 
(i) obuhvaća jaki lanac koji ima najmanje 90% identiteta sekvence prema aminokiselinskoj sekvenci SEQ ID NO:58;
ADM antibody or adrenomedullin antibody fragment or ADM non-IG scaffold for use in therapy of a chronic or acute disease of a patient according to any of the claims 1 to 13 or a combination according to claim 10 to be used in combination with ADM binding protein and/or further active ingredients. 
Postupak postterapijske kontrole in vitro kod pacijenata sa sepsom u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što navedeni ligand pokazuje afinitet vezanja na zreli ADM (amid 1-52) i/ili zreli ADM 1-52-Gly od najmanje 10/M'.
contacting the sample with AB-aggregates or with beads with AB-aggregates immobilised on their surface and allowing the AB-specific antibodies to bind to the AB-aggregates, and 
- - stavljanje u doticaj uzorka s AB-agregatima ili s kuglicama koje imaju AB-agregate imobilizirane na svojoj površini, te dopuštanje AB-specifičnim protutijelima da se vežu na AB-agregate, i
The peptide analog of claim 7(v), wherein glutamine at position 20 is replaced with lysine and the lipid moiety is covalently linked to the e-amino group of the lysine by one or more gamma-glutamic acid residues. 
Analog peptida prema zahtjevu 7(v), naznačen time, da je glutamin na poziciji 20 zamijenjen s lizinom i komponenta lipida je kovalentno vezana na e-amino-skupinu od lizina pomoću jednog ili više taloga gama-glutaminske kiseline.
A process for preparing an influenza vaccine from influenza virus that is grown in a culture of a Vero cell line, comprising a step in which seed virus and/or the vaccine and/or the culture is tested for the presence of an infectious agent that can grow in said cell line but that does not grow in embryonated hen eggs wherein said infectious agent is one or more of the following pathogens: Pneumovirinae; Metapneumoviruses of the Paramyxoviridae family; Rubulaviruses of the Paramyxoviridae family; Coronaviridae; Rhinoviruses of the Picornaviridae family; Varicella Zoster virus; BK polyomavirus, JC polyomavirus; Echoviruses; Coxsackieviruses of the Enteroviruses of the Picornaviridae family; Rotavirus; Porcine picornaviruses; Parvovirus; Circovirus; Chlamydia bacteria; mammalian Reoviridae. 
PATENTNI ZAHTJEVI Postupak za pripremanje cjepiva protiv gripe iz virusa gripe izraslog u kulturi Vero stanične linije, koji sadrži stupanj u kojem se uzgojeni virus i/ili cjepivo i/ili kultura testira na prisutnost infekcijskog agensa koji može rasti u navedenoj staničnoj liniji, ali koji ne raste u embriju kokošjih jaja, naznačen time, da je navedeni infekcijski agens jedan ili više od sljedećih patogena: Pneumovirinae; Metapneumovirusi iz familije Paramyxoviridae; Rubulavirusi iz familije Paramyxoviridae; Coronaviridae; Rhinovirusi iz familije Picornaviridae; Varicella Zoster virus; BK polyomavirus, JC polyomavirus; Echovirusi; Coxgackievirusi od Fnterovirusa iz familije Picornaviridae, Rotavirus, svinjski picornavirusi; Parvovirus; Circovirus; bakterija Chlamydia; Reoviridae kod sisavaca.
Detailed Description of preferred Embodiments of the Invention 
Datum objave europskog patenta:
The immunogenic composition of claims 1-9 or the vaccine of claim 10 for use in the treatment or prevention of disease caused by Streptococcus pneumoniae infection according to claim 12 wherein the disease is either or both of pneumonia or invasive pneumococcal disease (IPD) of elderly humans, exacerbations of chronic obstructive pulmonary disease (COPD) of elderly humans, otitis media of infant humans, meningitis and/or bacteraemia of infant humans, or pneumonia and/or conjunctivitis of infant humans. 
Imunogeni pripravak u skladu s patentnim zahtjevima 1-9 ili cjepivo u skladu s patentnim zahtjevom 10, naznačeni time što su namijenjeni upotrebi u liječenju ili sprječavanju bolesti uzrokovane infekcijom bakterijom Streptococcus pneumonijae u skladu s patentnim zahtjevom 12, gdje je bolest bilo pneumonija ili/i invazivna pneumokokna bolest (IPD) kod starijih ljudi, egzacerbacije kronična opstruktivne plućne bolesti (COPD) kod starijih ljudi, upala srednjeg uha kod ljudske dojenčadi, meningitis i/ili bakteriemija kod ljudske dojenčadi, ili pneumonija ifili konjunktivitis kod ljudske dojenčadi.
A process for separating water from sludge, comprising the steps of: 
Postupak odvajanja vode od mulja iz postrojenja za obradu otpadne vode, naznačen time što se sastoji u koracima:
The method according to claim 8, characterised in that the continuous bands of paper (1) are welded with continuous bands of mesh interchangeably. 
Metoda u skladu s patentnim zahtjevom 8, naznačena time, da su kontinuirane papirne trake (1) zavarene s kontinuiranim mrežnim trakama naizmjenično.
A composition according to claim 1 wherein said carbomer is at a concentration of 0.4 w/v%. 
Sastav prema zahtjevu 1, naznačen time, da se kod navedenog karboksivinilnog polimera radi o karbomeru s koncentracijom od 0,4 % (masa/volumen).
The product was extracted into dichloromethane (2×500 ml), washed with 10% sodium bicarbonate solution (500 ml), water, brine and dried over Na2SO4. 
Produkt se ekstrahira u diklorometanu (2x500 mL), ispere s 10 % otopinom natrijeva bikarbonata (500 mL), vodom i zasićenom otopinom NaCi, te osuši preko NaSO,.
The smoke inhalation device (100) according to one of the claims 4 and 5, wherein the timer (248) is further configured to accumulate the measured durations in a given period to activate a limit feature according to a substance distribution limit set in control logic of the controller (124; 224). 
E-cigareta (100) sukladno patentnom zahtjevu 1, naznačena time što je kontroler (124, 224) nadalje konfiguriran Za: usporedbu utvrđene količine prve tvari s unaprijed određenom granicom; i upravljati uređajem za prvo oslobađanje (118) na temelju usporedbe.
A method for facilitating processing of transactions within a computing environment, said method comprising: 
Postupak olakšavanja obrađivanja transakcija u računalnom okolišu, naznačen time što se navedeni postupak sastoji u:
The blister pack according to claim 1, in which said top layer comprises at least one aluminium layer. 
Blister pakiranje prema 1. zahtjevu, naznačeno time da navedeni gornji sloj (6) sadrži najmanje jedan aluminijski sloj (62).
The method according to claim 1, wherein the oxygen level of the gas exiting the waste treatment apparatus is maintained within the 3-10% range. 
Metoda prema bilo kojem od prethodnih zahtjeva, naznačena time da se razina kisika u plinu koji izlazi iz uređaja održava unutar raspona od 3-10%.
The coal feeder system of claim 8, wherein a lower portion of the riser is a moving expanded bed in proportion with an amount of control gas passing there through, a superficial gas velocity in the lower portion of the riser is in the range of about zero to one feet per second. 
Sustav opskrbe ugljenom (100) prema zahtjevu 7, naznačen time, da donji dio cijevi za podizanje je pokretni ekspandirani sloj u propocionalnom odnosu s količinom upravljanog plina koji prolazi kroz to, pri čemu se površinsko ubrzanje u donjem dijelu cijevi za podizanje, nalazi u rasponu od oko nula do jedne stope po sekundi (oko 30 cm/sek).
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) bixafen. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5- iDamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A PSD95 inhibitor for use according to any one of claims 8-10, wherein the thrombolytic agent is administered by localized administration to a site of impaired blood flow or wherein the reperfusion therapy is performed more than 3 hours after onset of ischemia, optionally, wherein the reperfusion therapy is performed more than 4.5 hours after onset of ischemia, or wherein the reperfusion therapy is performed more than 4.5 hours and less than 24 hours after onset of ischemia. 
Inhibitor PSD-95, namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što se reperfuzijsku terapiju provodi više od 3 sata nakon početka ishemije, što se, izborno, reperfuzijsku terapiju provodi više od 4,5 sati nakon početka ishemije, ili što se reperfuzijsku terapiju provodi više od 4,5 sati, a manje od 24 sata nakon početka ishemije.
The hemitartrate salt for use according to any one of Claims 21 to 23, wherein the salt is for administration at a twice daily dose of 50 milligrams. 
Spoj za uporabu prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time što je učinkovita količina dnevna doza od 100 miligrama.
in which R2 is as defined above is reacted in an inert solvent with a compound of the formula (IX) 
(VIII) gdje R* je kako je definirano u zahtjevima 1 do 4 reagira u inertnom otapalu sa spojem s formulom (IX)
Embodiment 3. The pharmaceutical composition for the use according to embodiment 1 wherein the crosslinked amine polymer has an equilibrium chloride binding capacity of at least 7.5 mmol/g in an aqueous simulated gastric fluid buffer ("SGF") containing 35 mM NaCl and 63 mM HCI at pH 1.2 and 37 °C. 
Farmaceutski pripravak prema bilo kojem od patentnih zahtjeva 1-3, gdje je umreženi aminski polimer sa ravnotežnim kapacitetom vezanja klorida od najmanje 7,5 mmol/g u vodenom puferu simulirane želučane tekućine ("SGF") koji sadrži 35 mM NaCI 1 63 mM FCI, pH 1,21 na 37%.
In its centre a similar motif of a smaller diameter was deeper engraved (see Figure 5a). 
U njegovom središtu ugravira so sličan motiv manjeg promjera (vidi Sliku 5a).
The aggregated CCE units may be numbered from 0 to 
(Ne | 1 ao Lk vrijednosti od 0 do
The solution was concentrated under reduced pressure and the residue was taken up in anhydrous dichloromethane (50 ml) once more. 
Otopina se koncentrira uz smanjeni tlak 1 ostatak se još jednom preuzme u anhidridni diklorometan (50 ml).
providing: upstream and downstream primers, each comprising a single-stranded DNA molecule of less than 30 nucleotides, at least a portion of which is complementary to sequence of the target molecule; 
(a) uzvodna početnica i nizvodna početnica, svaka sadrži molekulu jednolančane DNK gdje ima manje od 30 nukleotida, čiji je najmanje jedan dio komplementaran sekvenci ciljane molekule;
The process of claim 1 or 2, wherein the solution of hydrobromic acid in acetate acid comprises less than 500 ppm of metal ion impurities, less than 100 ppm of metal ion impurities, less than 10 ppm of metal ion impurities, or is free of metal ion impurities. The process of any one of claims 1-4, wherein the solution is 10-36% hydrobromic acid in acetate acid. 
Postupak prema patentnom zahtjevu 10, naznačen time, da otopina bromovodične kiseline u octenoj kiselini sadrži manje od 10 ppm nečistoća metalnim ionima. Postupak prema patentnom zahtjevu 11, naznačen time, da je otopina bromovodične kiseline u octenoj kiselini bez nečistoća metalnim ionima. Postupak prema bilo kojem od patentnih zahtjeva 1-12, naznačen time, da je boja otopine bromovodične kiseline u octenoj kiselini manja od 2000 APHA.
Combination for use according to claim 1 or 2 where the daily dose of R,R-glycopyrrolate is from 5 to 100 µg. 
Kombinacija za uporabu u skladu s patentnim zahtjevom 1 ili 2, naznačena time, da je dnevna doza R,R-glikopirolata od 5 do 100 µg.
A represents hydrogen, B represents methyl and B is in the trans-position to the oxygen; 
A predstavlja vodik, B predstavlja metil i B je u transpoziciji prema kisiku;
The metal substrate of statement 14, wherein the metal substrate is a negotiable coin. 
Metalna podloga u skladu s patentnim zahtjevom 9, naznačena time što je metalna podloga prenosiva kovanica.
T is H, a linear or branched, substituted or unsubstituted C1-C10 alkyl, linear or branched, substituted or unsubstituted C2-C10 alkenyl, linear or branched, substituted or unsubstituted C2-C10 alkynyl, optionally substituted cyclyl, optionally substituted heterocylcyl, optionally substituted aryl, optionally substituted heteroaryl, or PEG, wherein the backbone of C1-C10 alkyl, C2-C10 alkenyl, C2-C10 alkynyl optionally comprises one or more heteroatoms; n is an integer from 0-5; and 
T je H, linearni ili razgranati, supstituirani ili nesupstituirani C1-C10alkil, linearni ili razgranati, supstituirani ili nesupstituirani C2-C10alkenil, linearni ili razgranati, supstituirani ili nesupstituirani C2-C10alkinil, opcijski supstituirani ciklil, opcijski supstituirani aril, ili PEG, pri čemu kostur C1-C10alkila, C2-C10alkenila, C2-C10alkinila opcijski sadrži jedan ili više heteroatoma; i n je cijeli broj od 0-5, ili njegova sol, solvat ili ester.
A formulation for IV administration is prepared by dissolving the compound, for example as a pharmaceutically acceptable salt, to a concentration of 1% w/v in phosphate-buffered saline; and the solution is sterilized, for example by sterile filtration, and sealed in sterile containers containing, for example, 250 mg of a compound of this invention. 
Formulacija za IV davanje pripravljena je otapanjem spoja, na primjer kao farmaceutski prihvatljive soli, do koncentracije 1% tež/v u fosfatnom puferu; steriliziranje otopine, na primjer sterilnom filtracijom, i zatvaranjem u sterilne kontejnere koji sadrže, na primjer, 250 mg spoja iz izuma.
Materials and Methods 
Materijali i metode
The sunflower plant of claim 1, wherein said AHAS-inhibiting herbicide is an imidazolinone herbicide, a sulfonylurea herbicide, a triazolopyrimidine herbicide, a sulfonylamino-carbonyltriazolinone herbicide, or mixtures thereof. 
Suncokret u skladu s patentnim zahtjevom 1, naznačen time što je navedeni herbicid koji inhibira AHAS imidazolinonski herbicid, sulfonilurejski herbicid, triazolopirimidinski herbicid, sulfonilamino-karboniltriazolinonski herbicid, ili njihove smjese.
Here the ridges 28 .i are arranged on the side of the flange-like rim 20 facing away from the lid 14 . 
Kapsula (2) prema zahtjevu 1, naznačena time, da su grebeni (28.i) raspoređeni na obodnoj stijenci (16).
A method according to claim 1, characterized in that the polyolefin layer (5a) is a polyethylene layer, preferably in the form of a homopolymer or a copolymer of polyethylene. 
Postupak prema Zahtjevu 1, naznačen time, što je sloj polietilena u obliku homopolimera ili kopolimera etilena.
Trisaccharide derivate according to claim 1, wherein the substituted trisaccharide core is derived from raffinose, melezitose, maltotriose, nigerotriose, maltotriulose or kestose, preferably raffinose, melezitose or maltotriose, most preferably raffinose or maltotriose. 
Upotreba u skladu s patentnim zahtjevom 1, naznačena time što se supstituiranu trisaharidnu jezgru izvodi iz rafinoze, melezitoze, maltotrioze, nigerotrioze, maltotriuloze ili kestoze, po mogućnosti iz rafinoze, melezitoze ili maltotrioze, najpoželjnije iz rafinoze ili maltotrioze.
The method of claim 1, wherein the aminoglycoside is amikacin, the electrically neutral lipid comprises DPPC and cholesterol, and the liposome comprises unilamellar vesicles, multilamellar vesicles, or a mixture thereof. 
Farmaceutski pripravak za uporabu prema patentnom zahtjevu 4, naznačen time, što liposom sadrži jednolamelarne vezikule, višelamelarne vezikule, ili njihovu mješavinu.
The method according to claim 10, wherein the composition further comprises an osmolality adjusting agent selected from the group consisting of monosaccharides, disaccharides, oligosaccharides, and low molecular weight polyols. 
Jota-karagenan u antivirusno učinkovitoj količini za upotrebu prema patentnom zahtjevu 7, naznačeno time da pripravak nadalje sadrži sredstvo za podešavanje osmolalnosti odabrano iz skupine koju čine monosaharidi, disaharidi, oligosaharidi i polioli male molekulske mase.
the first lumen and the second lumen aggregating at a cannula nosepiece, the cannula nosepiece having separate flow paths to the patient for (i) the combined first therapeutic gas and triggering lumen and (ii) the second therapeutic gas lumen such that the first therapeutic gas and the second therapeutic gas do not mix in the cannula nosepiece; 
četvrti lumen je još jedan lumen dušikovog oksida za isporuku prvog terapijskog plina koji sadrži dušikov oksid pacijentu; i pri čemu prvi lumen dostavlja prvi terapijski plin u jednu nosnicu pacijenta,a četvrti lumen isporučuje prvi terapijski plin u drugu nosnicu pacijenta.
An ophthalmic device material of Claim 7 wherein the ophthalmic device material comprises from 0.3 to 2% (w/w) of a benzotriazole compound of Claim 1. 
Materijal za očne naprave u skladu s patentnim zahtjevom 7, naznačen time što materijal za očne naprave sadrži od 0,3 do 2% (tež./1ež.) benzotriazolskog spoja u skladu s patentnim zahtjevom 1.
A nutritional composition according to any one of embodiments 1-12 for use in improving body composition, the improvement of body composition being selected from the group consisting of increased lean body mass, decreased fat mass relative to total body weight, decreased visceral fat mass relative to total body weight, a decreased visceral fat mass relative to total fat mass, decreased fat accumulation and increased muscle mass, increased bone mass and increased bone mineral density. 
Nutritivni pripravak prema bilo kojem od zahtjeva 1-13 za uporabu u poboljšanju tjelesne građe, poboljšanje tjelesno građe se odabire iz skupine koju čine povećanje nemasnog dijela tjelesne težine, smanjenje masne težine u odnosu na ukupnu tjelesnu težinu, smanjenje tkivne masne težine tkiva u odnosu na ukupnu tjelesnu težinu, smanjenje tkivne masne težine tkiva u odnosu na ukupnu masnu težinu, smanjenje nakupljanja masti i povećanje mišićne mase, povećanje koštane mase i povećanje mineralne gustoće kostiju.
taken together form a 4 or 5-membered heterocyclic ring selected from the group consisting of azetidine, pyrrolidine, pyrazolidine, isooxazolidine, imidazolidine, oxazolidine, thiazolidine, and isothiazolidine; or 
uzeti zajedno tvore 4 ili 5-člani heterociklični prsten odabran od skupine koja se sastoji od azetidina, pirolidina, pirizolidina, izooksoazolidina, imidazolidina, okazolidina, tiazolidina i izotiazolidina; ili
The processing fluid of Claim 4, further comprising a hydrocarbyl succinimide; wherein the hydrocarbyl succinimide comprises the reaction product of polyisobutylene of molecular weight from 500 to 3000 Daltons and maleic anhydride. 
Tekućina za obradu prema zahtjevu 4, naznačena time što nadalje sadrži hidrokarbil sukcinimid; pri čemu hidrokarbil sukcinimid sadrži reakcijski produkt poliizobutilena molekulske mase od 500 do 3000 Daltona i maleinski anhidrid.
with a base, with heating, to form a reaction mixture; 
ostavlja reagirati s bazom, uz grijanje, zatim
The antagonistic antibody or antigen-binding fragment of claim 1 or 2 wherein said antibody comprises (a) a variable light (VL) chain region comprising a CDRL1 having the amino acid sequence set forth in SEQ ID NO: 99, a CDRL2 having the amino acid sequence set forth in SEQ ID NO: 104, and a CDRL3 having the amino acid sequence set forth in SEQ ID NO: 115; and (b) a variable heavy (VH) chain region comprising a CDRH1 having the amino acid sequence set forth in SEQ ID NO: 117, a CDRH2 having the amino acid sequence set forth in SEQ ID NO: 123, and a CDRH3 having the amino acid sequence set forth in SEQ ID NO: 135. 
Farmaceutski pripravak koji sadrži antagonističko anti-ljudsko IL13 antitijelo ili njegov fragment vezan za antigen koji se specifično veže na ljudski IL13 i fiziološki prihvatljiv nosač, naznačen time što navedeno anti-ljudsko IL13 antitijelo sadrži varijabilnu regiju teškog lanca koja sadrži regije koje određuju komplementarnost CDRH1, CDRH2 i CDRH3 koje imaju aminokiselinske sekvence od SEQ ID NO: 117, SEQ ID NO: 123, i SEQ ID NO: 135, odnosno, i varijabilnu regiju lakog lanca koja sadrži regije koje određuju komplementarnost CDRL1, CDRL2 i CDRL3 koji imaju aminokiselinske sekvence od SEQ ID NO: 99, SEQ ID NO: 104, i SEQ ID NO: 115, odnosno, i pri čemu je navedeno anti-ljudsko IL13 antitijelo ili njegov funkcionalni fragment formulirano da se daje intravenski, intraperitonealno, intramuskularno, subkutano ili oralno.